“A randomized, double-blind, placebo-controlled, Phase 1/2a trial protocol to assess the safety and efficacy of TAK-101 administered by microneedles in patients with celiac disease”, PPCR, vol. 8, no. 3, pp. 37–48, Dec. 2022, doi: 10.21801/ppcrj.2022.83.5.